Central Georgia News

Washington – On May 11, Representative Mike Collins’ (R-Ga.) bill, H.R. 1734, the Testing, Rapid Analysis, and Narcotic Quality (TRANQ) Research Act, unanimously passed the House of Representatives and is on its way to the Senate. Rep. Collins authored and introduced this legislation in March and was joined by Representative Yadira Caraveo (D-Colo.), Science Committee Chairman Frank Lucas (R-Okla.), and Ranking Member Zoe Lofgren (D-Calif.), who signed on as original co-sponsors. Collins issued this statement following the bill’s passage:

“The TRANQ Research Act is a key component in the fight against fentanyl, which has taken too many American lives. The research into deadly additives like the “Zombie Drug” this bill authorizes will help local law enforcement and border agents stay safe as they encounter this dangerous narcotic on the streets.”

Collins also spoke on the House Floor in advance of vote urging his colleagues to support this crucial legislation. This is his first bill to pass the House:

Click here to watch 

The TRANQ Research Act directs the National Institute of Standards and Technology (NIST) to deepen its partnerships and strategically focus on the science needed to detect, identify, and better understand synthetic opioids. One particularly dangerous fentanyl analogue contains xylazine—a veterinary tranquilizer. Tranq, also known as the “Zombie Drug,” has gruesome side effects. It causes large wounds that won’t heal and is resistant to standard opioid overdose treatments. Its use is skyrocketing across the country and contributing to an ever-growing number of drug overdoses. 

Original source can be found here.